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It is widely accepted that CF lung disease starts before clinical symptoms become apparent or
spirometry deteriorates. Computed chest tomography (CT) is the reference method for iden-
tifying structural changes in CF; however, radiation exposure limits its use as a monitoring tool.
It has been suggested that the Lung Clearance Index (LCI) measured by Multiple Breath
Washout (MBW) for assessing ventilation inhomogeneity is a more sensitive surrogate marker
than spirometry allowing non-invasive monitoring of CF lung disease.
The aim of this study was to prospectively investigate the diagnostic accuracy of the LCI in
comparison to CT in CF patients with early lung disease and normal FEV1 (>80% pred.).
MBW and ultra-low-dose CTwere performed in 34 patients (6e26 years). LCI was abnormal in
76.5% subjects. LCI and CT correlated significantly in 82.3%. LCI was related to presence and
extent of structural lung changes observed on CT with a sensitivity of 88%.
Diagnostic accuracy of the LCI for detecting CF lung disease in patients with normal FEV1 was
good when compared to CT. Results indicate that structural changes are unlikely if a normal
LCI is measured. We speculate that serial measurements of the LCI for assessing ventilation
inhomogeneity may help to identify early structural lung disease and help to reduce the indi-
vidual cumulative radiation dose. The LCI may be a suitable surrogate marker for monitoringrien-hospital-wesel.de (M. Gappa).
0 Elsevier Ltd. All rights reserved.
Sensitivity of Lung Clearance Index and CT in CF 1835progression of CF lung disease and effect of treatment in both, clinical care and research
settings.
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While life expectancy and quality of life have greatly
improved for patients with Cystic Fibrosis (CF) over the last
decades, lung disease remains the main cause of morbidity
and mortality.1,2 It is widely accepted that the lungs of
infants born with CF are largely normal at birth, but that
pulmonary disease starts during the first months of life.3
Measurements of lung function are routinely performed
from4 to 5 years of age to assess extent and progression of CF
lung disease. However, it is now consensus that forced
expiratory volume in 1 s (FEV1) is not accurate for assessing
early pulmonary disease.4 Structural pulmonary changesmay
be present in children with normal conventional lung func-
tion tests.5,6 Despite increasing scientific evidence for its low
sensitivity, FEV1 remains themost commonly used parameter
of lung function for both routine clinical assessment and as
a surrogate outcome marker in clinical studies.
Development of bronchiectasis is the most important
component of CF lung disease. Computed chest tomography
(CT) is the reference method for detecting early and
advanced lung changes in these patients.
CT of the lungs has received increasing attention in
recent years for particularly assessing early stages of CF
lung disease that are not detectable by conventional
spirometry.7,8 Attempts to use conventional high resolution
CT as an outcome parameter in clinical trials with young
children are promising.9,10 However there remains concern
regarding the radiation exposure, particularly with respect
to the increasing life expectancy of patients with CF thus
limiting repeated use in clinical monitoring programs.
International efforts for developing a standardised low-
dose protocol are ongoing, aiming both, to acquire high
resolution CT scans that provide information relevant to the
routine clinical care of patients with early lung disease and
to minimise radiation exposure.11
When performing CTs in younger patients it should be
considered that this is a time consuming and incriminating
procedure that requires sedation or general anaesthesia.
Another disadvantage may be that CT could increase
anxiety for both clinicians and families, as long as it has no
influence on treatment decisions.12
Inert gas Multiple Breath Washout (MBW) for assessing
ventilation inhomogeneity (VI) is a non-invasive and safe lung
function test that has been shown tobe sensitive for detecting
early pulmonary changes in CF.13e16 Several indices of venti-
lation inhomogeneity, such as the Lung Clearance Index (LCI)
can be calculated from the washout curves describing pres-
ence and extent of VI. The LCI reflects overall VI within the
peripheral and communicating zones of the lungs. Compared
to spirometry, a large proportion of patients had abnormal LCI
results, even if FEV1 was above 80% predicted. In our initial
study with CF patients and healthy controls, 20/26 (77%)
children and adolescents with CF had increased LCI values,
while FEV1 was decreased in 10/26 (38.5%).
17It has recently been reported that parameters of ventilation
inhomogeneity measured by MBW may be as good as CT for
detecting pulmonary changes in CF patients.14 LCI had a high
sensitivity to detect abnormal imaging results. This retrospec-
tive analysis included patients representing the entire range of
CF lung disease, i.e. FEV1 between 44 and 127% predicted.
In patients with CF and normal spirometry there are no
prospective studies which have assessed the diagnostic
accuracy of LCI compared to CT. However, particularly
patients with early lung disease may benefit from intro-
ducing MBW as a sensitive, yet non-invasive tool into clin-
ical management programs. This could allow earlier
diagnosis of CF lung disease and subsequently, development
and evaluation of new treatment strategies that aim to halt
progression before irreversible lung damage has occurred.
Therefore, this prospective study aimed to prove diag-
nostic accuracy of the LCI as the index test in comparison to
ultra-low-dose CT scans for identifying early lung changes in
children, adolescents and young adults with CF and normal
FEV1 (>80% pred.).
We hypothesised that MBW is as sensitive as ultra-low-
dose CT scans for detecting early lung changes in young
patients with CF and may thus be used as a non-invasive
surrogate marker for both, clinical trials and clinical
monitoring.
Methods
Study design
This is a prospective, cross-sectional observational study in
a group of young patients with CF and normal FEV1, where
MBW was compared with routine diagnostic ultra-low-dose
chest CT and spirometry.
Setting
Measurements were carried out at the Department of
Paediatrics of the Medical University Innsbruck in May and
August 2007. Outpatients in a stable clinical status were
studied during a routine visit to the CF Centre. Because at
that time only one set of equipment was available, one of
the authors (SF) performed MBW using an ultrasonic
prototype equipment which had been transferred to Inns-
bruck only for the purpose of the study. The routine diag-
nostic workup for CF patients was performed as usual.
A quality management system for diagnostic and thera-
peutic policies is in place at the CF centre that had been
certified according to DIN EN ISO 9001:2008. Treatment
procedures are in accordance with the standards of care
reported by the European Cystic Fibrosis Society.18
Prophylactic antibiotics are not used routinely. First
time or intermittent Pseudomonas aeruginosa (PSA) infec-
tion is treated using inhalative antibiotics. For patients with
1836 H. Ellemunter et al.chronic PSA colonisation 4 cycles of intra venous antibiotic
treatment per year are recommended.
An acute pulmonary exacerbation is diagnosed if at least
2/6 of the following symptoms are present: decreased general
condition, weight loss, increased/changed sputum, increased
coughing, >10% decrease of lung function and dyspnoea.
Patients with an acute pulmonary exacerbation receive an i.v.
or oral and inhalative course of antibiotic treatment in case of
an additional positive sputum culture or deep throat swap.
Dornase alpha and/or hypertonic saline is used to
improve mucociliary clearance and to reduce the frequency
of respiratory exacerbations.
Documentation of a stable clinical status includes
normal physical condition, absence of recurrent acute
pulmonary exacerbations, stable spirometry and stable CT-
score within the preceding year.
Newborn screening (NBS)was implemented inTyrol in 1992.
Participants
The CF patient database at the Medical University Inns-
bruck which contains information on 138 patients was
screened to identify patients who had a normal FEV1
defined as the annual average value >80% of the predicted
normal value at a minimum of 4 lung function measure-
ments per year.
Forty-one eligible subjects were asked to participate in
the study. Patients were informed that they would have to
spend additional time at the centre to carry out the MBW
measurements.
The study was approved by the local ethics committee.
Parental informed written consent and patient assent was
obtained prior to the measurements.
Protocol
After reception at the centre, patients had a session of
standard physiotherapy. MBW measurements and spirom-
etry were performed subsequently: Each subject aimed to
perform three technically acceptable washouts, but at
least two which differed by less than 10% functional
residual capacity (FRC). During measurements, patients
were in a sitting position wearing a nose clip, breathing
through a mouthpiece while watching a video.
Spirometry was then performed according to ATS/ERS
recommendations.19 After completion of lung function
measurements patients visited their physician.
CT scans were timed as usual, 12 months after the
previous routine CT. This resulted in a median interval
(range) of 0.0 (243 to 158) days between CT and MBW. The
reason being that, MBW equipment was only available for
a limited time frame. However CT scans were scheduled
according to the patient’s individual protocol with intervals
of one year. It was considered unethical to either shorten or
lengthen this imaging interval for research purposes.
Measurements
MBW measurement and variables
The ultrasonic technology and the side stream ultrasonic
flow sensor (USFS) prototype system (EasyOne Pro, MBWModule, ndd Medizintechnik AG, Zurich, Switzerland) was
described previously.17,20e22 Briefly, the system consists of
a mainstream ultrasonic transducer for flow sampling,
a side stream ultrasonic transducer for temperature inde-
pendent sampling of the molar mass (MMss) and a side
stream infrared CO2 analyser (DUET ETCO2 Module, Welch
Allyn OEM Technologies, Beaverton). The gas bias flow
system that provides valve-controlled tracer gas delivery
containing 4% sulfurhexafluoride (SF6), 21% oxygen and
balanced nitrogen (Linde AG, Germany) is automatically
removed during the washout phase, thus reducing the
apparatus’ dead space to a minimum.23 Calibration of the
system and time delay correction of the side stream signals
were performed as described previously.
To start a measurement, subjects breathed quietly
through the mouthpiece. The bias flow is automatically
switched to the tracer gas at end expiration. Equilibrium is
defined as a visually stable plateau of the MMss signal. The
bias flow is then switched back into room air for washout,
which is finished when the tracer gas concentration falls
below 2.5% (1/40) of the starting level.
FRC was calculated from the cumulative volume (CEV) of
expired SF6 divided by the difference between end-tidal gas
concentration at the start and end of the washout. LCI was
calculated as the CEV, divided by the FRC. Analysis has
been described in detail previously and was performed
according to recommendations published recently.21,24 For
the LCI, the upper limit of normal (7.0) was defined
according to published normal data assessed in healthy
children and adolescents and with the same equipment
used in this study.23
A complete MBW measurement took about 30e40 min,
and measurements were well tolerated even by younger
children. WBreathª software (version 3.24) was used for
data acquisition, storage and analysis.
Spirometry and body mass index
Spirometry was performed according to ATS/ERS stan-
dards19,25 using a Master Screen Bodyplethysmograph (Erich
Jaeger, Germany). Body mass index (BMI) percentiles were
calculated using German reference values.26
Ultra-low-dose chest computed tomography
The monitoring programme at the Cystic Fibrosis Centre in
Innsbruck includes yearly ultra-low-dose volumetric thin-
section multi-detector computer tomography scanning
(MDCT) in all CF patients. Axial images were obtained in
a supine position during a single deep inspiration hold and
covered the entire lung parenchyma from the base to the
apex of the lung using a 16- or 64-slice CT scanner (GE
Lightspeed 16 or Lightspeed Volume CT, Milwaukee, USA)
with the following settings: 120 keV, 10 mA, rotation time
0.8 s, 1.25 mm sections, 1.25 mm interval. The displayed
dose length product (DLP) ranged from 8.50 to
22.52 mGy*cm, and the calculated estimation of mean
effective dose generated by this protocol yielded 0.15 mSv
(range: 0.12e0.33 mSv).27
Scans were scored by two independent experienced
radiologists of the Department of Radiology (KMU, MCF)
who were blinded to the patients’ identity, to their clinical
status and to the results of lung function tests. A modified
Bhalla score28,29 was used, where a score of 25 points
Table 1 Clinical and demographic characteristics of
patients.
CF patients
(nZ 34)
Age [years] 14.1 (6.2e 26.4)
Males:females 20:14
Weight [kg] 42.9 (17.7e 74.8)
Height [cm] 149.5 (113e 183)
Body mass index [Z-score] 0.30 (3.8e 1.6)
CFTR Genotype
F508del homozygous 20
F508del heterozygous 12
Other mutations 2
P. aeruginosa positive 10
Pancreatic insufficiency 34
Type of CF manifestation
Screening only 13
Gastrointestinal symptoms 10
Pulmonary symptoms 3
Meconium ileus 4
Sibling 4
Results are means and ranges or numbers of patients.
Sensitivity of Lung Clearance Index and CT in CF 1837represents the best and a score of 0 the worst possible
result. For the purpose of the present analysis, values of 25
or 24 points were regarded as normal. In addition, a densi-
tometry protocol was used to quantify areas of emphy-
sema.30 Results are expressed as a percentage of voxels
with a density below ‑950 Hounsfield units (normal value:
<5%). As an index for disease in the small airways and of
luminal impaction with mucus, pus, or fluid, the tree-in-bud
sign was specifically searched for and quantified.31
Other tests
Additional information on CF patients concerning genotype,
microbiology, pancreas function and type of CF manifes-
tation was obtained from in and outpatient records and
from the CF patient database.
Statistics
Group data for age, weight, height, BMI and CT-score are
reported as mean and range. Individual data for LCI are
reported as the mean or standard deviation score (Z-
score)25 of 2e3 technically acceptable measurements
within one test occasion for each subject. Group data are
expressed as mean range or as Z-score.
Parameters of spirometry are expressed as Z-scores (SD)
according to the reference equations by Zapletal.25 A
Pearson correlation analysis was used to investigate corre-
lations between CT-score, LCI and FEV1. Cross tables were
used to compare the proportion of abnormal CT results to
the proportion of abnormal LCI and spirometry results and
to calculate sensitivity, specificity and positive and nega-
tive predictive value. The statistical package used was SPSS
version 16.0 for Windows.
Results
Patient characteristics
Forty-oneCFpatientswithnormalFEV1participatedinthestudy.
All participants were in a stable clinical status. MBW measure-
ments were feasible and well tolerated by all participants.
Seven patients were excluded due to limited compliance
or unstable breathing pattern, leaving 34 subjects for final
analysis. Thirty-three/thirty-four data sets were complete,
one MEF25 value is missing. Subject characteristics and
clinical information are presented in Table 1.
Twenty-one/thirty-four patients were diagnosed within
the neonatal period. Mean age (SD) at diagnosis in patients
presented a pulmonary and/or gastro intestinalmanifestation
of CF during childhood (nZ 13) was 2.2 (4.0) years (Table 1).
A single pulmonaryexacerbationoccurred in 1/34 between
the date of CTand the date of LCI and in 7/34 within the year
preceding the date of LCI. None of the patients suffered from
recurrent exacerbations within this time period.Outcome data
Results of Spirometry, MBW and CT results are summarised
in Table 2. In accordance with inclusion criteria, all
patients had a normal FEV1.In contrast to Spirometry, MBW measurements revealed
abnormal results in the majority of patients: LCI was
increased in 26/34 patients (76.5%).
CT demonstrated an abnormal modified Bhalla score in
26/34 (76.5%), abnormal densitometry in 17/34 andpresence
of a tree-in-bud pattern in 13/34 of the patients. The most
frequent abnormalities observed using the Bhalla score were
airway wall thickening, severe bronchiectasis and bronchi-
ectasis expanding to peripheral lung regions. Mucus plugging
and consolidations were also present in many patients,
whereas none had bullae or abscesses (Tables 2 and 3).
Good concordance was observed between LCI and CT-
score. 23/34 patients (67.6%) demonstrated both, increased
LCI and structural changes on CT. 5/34 patients (14.7%) had
normal results in both measurements. Thus, in 28/34
patients (82.3%) LCI corresponded with CT-score. Discordant
results were obtained in 3 patients with a normal LCI and
decreased CT-scores of 23, 22, and 18 points, and in 3
patients with a normal CT-score and increased LCI (7.1e8.5).
There was a significant linear correlation between CT-score
and LCI (Fig. 1); whereas no such correlation was observed
betweenCT-score and FEV1 (Fig. 2). LCIwasmore sensitive in
detecting pulmonary changes than FEV1 (Fig. 3). LCI was as
high as 10.6 and CT-scores as low as 11 points in the presence
of normal FEV1 (Figs. 2 and 3). Sensitivity (95% confidence
interval) of the LCI to detect structural lung damage was 88%
(69:97) and specificity (95% confidence interval) was 63%
(26:90) when compared with the CT as the reference test.
The positive predictive value, indicating structural lung
disease in presence of an increased LCI, was 88% and the
negative predictive value, indicating normal lung structure
in presence of a normal LCI, was 63%.
In contrast, sensitivity of MEF25 to detect structural lung
damage observed with CT as the reference test was 42%.
Fig. 4a illustrates that the mean LCI was elevated in
patients with bronchiectasis, mucus plugging or airway wall
Table 2 Results of spirometry, MBW and ultra-low-dose CT.
CF patients (nZ 34)
mean (range)
CF patients with abnormal
results (%)
Spirometry (Z-scoresa)
FEV1 0.7 (0.9 to 5.5) 0 (0)
FEV1/FVC 1.0 (1.4 to 3.4) 0 (0)
MEF75 0.4 (1.8 to 3.2) 0 (0)
MEF50 0.2 (3.2 to 3.1) 2 (5.9)
MEF25 1.30 (6.5 to 3.0) 13 (38.2)
MBW
LCIb 8.0 (6.1e 10.6) 26(76.5)
CT
Bhalla Scorec 20.3 (11e 25) 26 (76.5)
Densitometry (<950%)d 5.3 (0.1e 17.7) 17 (50)
TIB Phenomenon (%)e 15.0 (0e 55.8) 13 (38.2)
a Normal value: >2.
b Normal value: 7.0.
c A score of 25 represents the best and a score of 0 the worst possible score (a score of >23 (96%) was defined as normal).
d Estimated normal value <5%.
e Tree-in-Bud Phenomenon (%).
1838 H. Ellemunter et al.thickening, and it increased with the extent of abnormali-
ties (Bhalla Score 0e3 points). Furthermore, LCI was
elevated in patients with abnormal densitometry and
positive tree-in-bud sign (Fig. 4a). In contrast, FEV1 was not
related to the presence and extent of abnormalities
observed on CT (Fig.4b).Discussion
Our study demonstrates good diagnostic accuracy of the LCI
when compared to the reference standard CT in young
patientswithCFandnormal FEV1. Results ofMBWandCTwere
concordant in more than 80% of patients. Thus, MBW is a non-
invasive surrogate marker to screen for structural abnormal-
itieswithout radiation exposure.Our study confirms that evenTable 3 Morphologic changes on ultra-low-dose CT.
Patients with abnormal
results (%)
Degr
1 po
Airway wall thickening 76.5 76.5
Bronchiectasis
Severity 76.5 64.7
Expansion 70.6 32.4
Peripheral expansion 55.9 41.2
Mucus plugging 44.1 20.6
Consolidations 38.2 35.3
Emphysema 2.9 2.9
Abscess 0 0
Bullae 0 0
Abnormal densitometry 50.0 50.0
Tree-in-bud sign 38.2 61.8early structural lung disease observed on CTcan indirectly be
detected by assessing ventilation inhomogeneity.
To our knowledge, this is the first prospective study that
confirms good diagnostic accuracy of MBW compared to CT in
patients with normal FEV1, thus adding new information to
the field.
MBW and CT revealed pulmonary disease in almost 80%
of the study population with normal FEV1. This is not
surprising, since a recent study showed a high degree of
abnormalities even in infants diagnosed by NBS.3
Even in this relatively homogeneous group with at most
early lung disease, defined as normal FEV1 and absence of
clinical symptoms, we found a significant correlation
between morphological changes present on CT that were
reflected by impaired ventilation inhomogeneity, in sense
of an increase in LCI.ee of pathology (modified Bhalla score)
int 2 points 3 points
0 0
11.8 0
29.4 8.8
11.8 2.9
20.6 2.9
2.9
0
0 0
0 0
Figure 1 LCI Z-score vs. CT-score. Vertical line: lower limit
of normal for CT-score (>23 points). Horizontal line: upper
limit of normal for LCI Z-score (Z2).
Figure 3 LCI Z-score versus FEV1 Z-score. Vertical dotted
line: lower limit of normal for FEV1 Z-score (Z2). Horizontal
dotted line: upper limit of normal for LCI Z-score (Z2).
Sensitivity of Lung Clearance Index and CT in CF 1839A previous retrospective analysis in 44 CF patients
covering a much wider range of pulmonary function
abnormalities led to comparable results.14 Of the 27
patients with abnormal HRCT-scores 25, 17 and 7 had
abnormal results for LCI, MEF25 and FEV1 respectively.
Sensitivity of the LCI to detect abnormalities in CT scans
was comparable to our study. Whereas none of the 7
Swedish patients with a normal FEV1 had a normal CT-score,
we observed a normal CT and FEV1 in 8/34 patients. This
may be due to patient selection, as well as methodological
differences in CT scanning protocols, definitions of a normal
CT and scoring methods.
In accordance with previous publications11,32,33 bron-
chiectasis and airway wall thickenings were the most
frequent structural abnormalities in our patients with early
lung disease. Mean LCI for the subgroups increased with the
degree of morphologic abnormalities observed using the
Bhalla Score (Fig. 4a).
In contrast to imaging which allows location and speci-
fication of structural abnormalities in the larger airways,Figure 2 FEV1 Z-score vs. CT-score. Vertical line: lower limit
of normal for CT-score (23 points). Horizontal line: lower
limit of normal for FEV1 Z-score (Z2).measurement of the LCI simply mirrors overall ventilation
inhomogeneity within the peripheral and communicating
zones of the lungs. Presence of ventilation inhomogeneity
may thus be due to different underlying pathophysiological
mechanisms. In addition, the CT-score covers a number of
different structural abnormalities that may be distributed
all over the lungs or only in a single area of the lungs. As the
combination and the extent of morphologic lung changes
observed in CT scans have been shown to be very variable
among individuals, our data don’t allow direct allocation of
LCI levels to specific morphologic lung changes described
with the modified Bhalla score. These differences between
CT scanning and measurement of the LCI may be reflected
by a relatively low coefficient of variation.
However, the LCI as a surrogate marker demonstrated
good sensitivity and acceptable specificity to detect struc-
tural changes in CF lungs observed by ultra-low-dose CT.
The relevance of these findings as well as the impor-
tance of minor abnormalities, such as Grade 1 bronchiec-
tasis or mucus plugging, can be better interpreted when
longitudinal data become available.
The advantage of using MBW compared to ultra-low-dose
CT is that even the relatively low radiation burden could be
spared. Due to our results and published data, an abnormal
CT is unlikely in presence of a normal LCI. Integration of
MBW into clinical care programs for patients with CF may
facilitate the decision for or against CT scanning in indi-
viduals and may thus help to prevent redundant radiation
exposure.
MBW only requires patience of both patients and inves-
tigators, and it can be repeated as often as necessary.
Furthermore, the equipment used for the present study is
easy to use, hygienically safe,22 reliable and is now avail-
able for multi-centre use. This study is thus relevant for
both, clinical and research purposes in CF care.
Our results again demonstrate lacking sensitivity of the
FEV1: In presence of increased LCI or decreased CT-scores
there is not even a trend to lower FEV1 Z-scores within the
normal range. This is likely to be due to the known variability
of repeat spirometricmeasurements. Additionally Figs. 2 and
3 illustrate, that a normal FEV1 covers a wide range of
Figure 4 a)Mean LCI Z-score (y-axis) vs. degree of abnormali-
ties (x-axis) observed by Bhalla Score (0e3 points), Densitometry
(0Z normal, 1Z abnormal) and quantitative assessment of tree-
in-bud sign (0Znormal, 1Z abnormal). Upper limit of normal for
LCI Z-score: þ2, abnormal values above þ2. Dotted lines define
the normal range of þ/2 SD. Dots: general extent of bronchi-
ectasis. Rings: severity of bronchiectasis. Solid triangles:
peripheral extent of bronchiectasis. Triangles: mucus plugging.
Crosses: airway wall thickening. Stars: Densitometry. Arrows:
tree-in-bud sign. Group sizes for reported data ranged from nZ 3
to nZ 26 (median nZ 11) (Only one patient received 3 points for
peripheral extent of bronchiectasis and 3 points for mucus plug-
ging. This data were excluded for this figure due to small group
size). b) FEV1 Z-score (y-axis) vs. degree of abnormalities (x-axis)
observedbyBhallaScore (0e3points),Densitometry (0Znormal,
1 Z abnormal) and quantitative assessment of tree-in-bud sign
(0Z normal, 1 Z abnormal). Lower limit of normal for FEV1 Z-
score: -2, abnormal values below 2. Dotted lines define the
normal range of þ/2 SD. Dots: general extent of brochiectasis.
Rings: severity of brochiectasis. Solid triangles: peripheral extent
of brochiectasis. Triangles: mucus plugging. Crosses: airway wall
thickening. Stars: Densitometry. Arrows: tree-in-bud sign. Group
sizes for reported data ranged from n Z 3 to n Z 26 (median
nZ 11) (Only one patient received 3 points for peripheral extent
of brochiectasis and 3 points for mucus plugging. This data were
excluded for this figure due to small group size).
1840 H. Ellemunter et al.abnormalities demonstrated by markedly increased LCIs up
to 10.6 and markedly decreased CT-scores down to 11 points
and not eas might be expectede only slightly abnormal
results that reflect early CF lung disease.
Our study had several limitations:
First, the study design was cross-sectional and only
longitudinal data points would allow deeper insights into
evolution and prognosis of lung disease in CF.
Second, we investigated children from age 4 onwards,
although structural lung damage may already be present
in asymptomatic infants diagnosed by NBS.3 However,
the aim of our study was to compare LCI and chest CT in
patients with normal FEV1, requiring acceptable spiro-
metric manoeuvres from all patients. In addition the
equipment has been validated for use in children aged 4
years and older.17
Third, the CT scanning protocol differed from published
protocols. The present ultra-low-dose protocol without
expiratory scans has been used at the Innsbruck CF
centre for many years, so it was ethically not justified to
change the procedure for this observational study.
However, including the tree-in-bud phenomenon and CT
densitometry into analysis was an attempt to quantify
early changes reflecting ventilation impairment in the
more peripheral zones of the lungs. We are aware, that
these data are very preliminary and that this approach
has not been fully validated yet. However, our results for
these parameters from inspiratory scans only were
slightly disappointing.
Fourth, the threshold for an abnormal CT-score was set
to <24 points using a modified Bhalla score, since no
scoring system has been developed which focuses on
early changes in the lung.11 In addition, there is no
consensus yet, as to when a CT has to be considered
abnormal. Very little information exists, whether
singular changes will persist or are reversible.
Finally, restricted availability of the MBW equipment in
Innsbruck and required strict adherence to one year inter-
vals of repeat CTs in any of the participants explains the
time gap between MBW and CT. Accepting this limitation
due to ethical reasons may limit interpretation of our
results. However our study population demonstrating
normal FEV1 and a stable clinical status represents CF
patients with early lung disease. This may justify the
assumption that structural lung changes, if present, may
progress rather slowly in this population.
In summary, we have shown that 4/5 patients with
normal FEV1 had evidence of structural lung disease on
ultra-low-dose chest CT and an increased LCI indicating
functional abnormalities in the lung periphery. Therefore,
the LCI could be used as a surrogate marker for detecting
early CF lung disease and may thus help to minimise radi-
ation burden.
An elevated LCI indicates presence of lung disease,
potentially requiring more intensive treatment. However,
before such recommendations can be made, additional
prospective and particularly, longitudinal data are needed.
Longitudinal data are additionally required to investi-
gate whether the LCI can contribute to improve the
Sensitivity of Lung Clearance Index and CT in CF 1841prognosis of patients with CF regarding quality of life and
mortality and whether the LCI can be used as an outcome
parameter for clinical trials.
Both, ultra-low-dose CT and MBW contribute to early
detection of lung disease despite a normal FEV1 and absence
of clinical symptoms and may thus be of value for further
improving management of lung disease for patients with CF.Acknowledgements
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